FY2025 · ended Jan 2, 2026 · Revenue $2.32B, +7.0% YoY · Filed Feb 10, 2026
Exelixis, Inc. (EXEL) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Jan 2, 2026, it reported revenue of $2.3 billion and net income of $782.6 million. Free cash flow was $875.8 million. As of Oct 2, 2026 it held $1.4 billion in cash and investments and $162.2 million in total debt.
Revenue (TTM)
$2.50B
+9.1% vs year-ago TTM
Net income (TTM)
$885.14M
+30.6% vs year-ago TTM
Operating cash flow (TTM)
$1.17B
+48.3% vs year-ago TTM
Free cash flow (TTM)
$1.16B
+48.9% vs year-ago TTM
EPS (TTM)
$3.34
+41.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
259.71M
-7.2% vs prior year
Net cash
$1.24B
as of Oct 2, 2026
Operating margin
40.2%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- EXEL (Nasdaq)
- Fiscal year ends
- January 1
- Incorporated in
- DE
- Headquarters
- Alameda, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 939767
- Former names
- EXELIXIS INC (until Sep 12, 2012)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Neurocrine Biosciences Inc NBIX
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Jan 2, 2026 |
FY 2024 Jan 3, 2025 |
FY 2023 Dec 29, 2023 |
FY 2022 Dec 30, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.3B | $2.2B | $1.8B | $1.6B | $1.4B |
| Operating income | $872.2M | $604.6M | $170.9M | $201.5M | $286.7M |
| Net income | $782.6M | $521.3M | $207.8M | $182.3M | $231.1M |
| Diluted EPS | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 |
| Operating cash flow | $884.3M | $700.0M | $333.3M | $362.6M | $400.8M |
| Free cash flow | $875.8M | $671.5M | $292.9M | $334.9M | $346.6M |
| Total assets | $2.8B | $2.9B | $2.9B | $3.1B | $2.6B |
| Total liabilities | $683.1M | $703.5M | $678.4M | $583.1M | $405.6M |
| Stockholders' equity | $2.2B | $2.2B | $2.3B | $2.5B | $2.2B |
| Cash and investments | $1.7B | $1.7B | $1.7B | $2.1B | $1.8B |
| Total debt | $200.9M | $215.8M | $215.7M | $207.8M | $56.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Other events
|
Sep 11, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Other events
|
Aug 31, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jul 3, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
All 1003 Exelixis, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.